ARTICLE SUMMARY:
In this Q&A, Senseonics President and CEO Tim Goodnow discusses the US launch of Eversense, a first-of-its-kind 90-day implantable continuous glucose monitoring system, as well as the company’s well-stocked product pipeline, and the challenges it faces in the rapidly expanding and fiercely competitive US CGM space.
As the newest competitor in the US continuous glucose monitoring (CGM) market, with its recently launched 90-day Eversense implantable CGM sensor system, Senseonics Holdings Inc. is entering the CGM space at a time of unprecedented market growth and rapidly expanding patient and physician awareness.
